Interleukin-6
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Circulating IL-6 is elevated in COPD patients compared to healthy subjects, both during and outside exacerbations, and is associated with reduced quadriceps strength.
“Circulating IL-6 is also classically elevated in COPD patients compared to healthy subjects, both during and outside exacerbations [44] and associated with reduced quadriceps strength [45].”
From Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting (2023) · cites this paper as [44]
The Interleukin-6 section links circulating IL-6 to COPD exacerbations, and the References list a study reporting elevated serum IL-6 during acute exacerbations. But its comparison with healthy controls during clinical stability concerns CRP, fibrinogen, leukocytes, and platelets—not IL-6—so it does not establish that part of the claim. Reduced quadriceps strength has a separate citation [45] in the citing sentence and is not judged against this source. (LLM, conf=0.83)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 12
- Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:2645-2653
- Sin DD, Man SF. Why are patients with chronic obstruc- tive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107:1514 -1519
- Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflam- mation: a systematic review and a meta-analysis. Thorax 2004; 59:574 -580
- Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111:1805-1812
- Walter R, Wilk J, Larson M, et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008; 133: 19 -25 6
- Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005; 23:1-21
- Garrod R, Marshall J, Barley E, et al. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2007; 16:236 -240
- Yende S, Waterer GW, Tolley EA, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006; 61:10 -16
- Bolton CE, Evans M, Ionescu AA, et al. Insulin resistance and inflammation: a further systemic complication of COPD. COPD 2007; 4:121-126
- Eddahibi S, Chaouat A, Tu L, et al. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hyperten- sion in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3:475-476
- Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84:210 -215
- Kuhn C III, Homer RJ, Zhu Z, et al. Airway hyperrespon- siveness and airway obstruction in transgenic mice: morpho- logic correlates in mice overexpressing interleukin (IL)-11 and IL-6 in the lung. Am J Respir Cell Mol Biol 2000; 22:289 -295
Cited by
Sorted by citations
Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting
Henrot, P., Dupin, I., Schilfarth, P., Esteves, P., Blervaque, L., Zysman, M., Gouzi, F., Hayot, M., Pomiès, P., & Berger, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076454 · Cited by 85 · see citing works
- Authors
- Sin, D. D., & Man, S. F. P.
- Affiliations
- University of British Columbia (CA)
- Corresponding author
- Sin, Don D.
- ORCID
- Sin, Don D.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 133
- Issue
- 1
- Pages
- 4-6
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W1997243548
- Cited by
- 25
- References
- 0
- Citations by year
- 2023: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2016: 3 · 2015: 1 · 2014: 3 · 2013: 6 · 2012: 2
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- CHEST Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
- Keywords
- interleukin-6, chronic obstructive pulmonary disease, systemic inflammation, airway inflammation, biomarkers, inflammatory signaling, proteomics, disease progression
- MeSH terms
- Forced Expiratory Volume, Humans, Inflammation, Biomarkers, Interleukin-6, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
